Drug Substitution

"Drug Substitution" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The practice of replacing one prescribed drug with another that is expected to have the same clinical or psychological effect.

Descriptor ID	D057915
MeSH Number(s)	E02.319.307.312 N02.421.668.778.500.312
Concept/Terms	Drug Substitution Drug Substitution Drug Substitutions Substitution, Drug Substitutions, Drug Therapeutic Substitution Substitution, Therapeutic Substitutions, Therapeutic Therapeutic Substitutions Drug Switching Drug Switchings Switching, Drug Switchings, Drug Generic Substitution Generic Substitution Generic Substitutions Substitution, Generic Substitutions, Generic

Below are MeSH descriptors whose meaning is more general than "Drug Substitution".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Therapeutics [E02]
Drug Therapy [E02.319]
Drug Prescriptions [E02.319.307]
Drug Substitution [E02.319.307.312]
Health Care [N]
Health Care Facilities, Manpower, and Services [N02]
Health Services [N02.421]
Pharmaceutical Services [N02.421.668]
Prescriptions [N02.421.668.778]
Drug Prescriptions [N02.421.668.778.500]
Drug Substitution [N02.421.668.778.500.312]

Below are MeSH descriptors whose meaning is related to "Drug Substitution".

Below are MeSH descriptors whose meaning is more specific than "Drug Substitution".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Drug Substitution" by people in this website by year, and whether "Drug Substitution" was a major or minor topic of these publications.

Bar chart showing 26 publications over 10 distinct years, with a maximum of 4 publications in 2015 and 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2010	1	0	1
2011	0	3	3
2013	2	1	3
2014	1	0	1
2015	2	2	4
2016	1	2	3
2017	0	4	4
2018	1	1	2
2019	0	3	3
2020	1	1	2

Below are the most recent publications written about "Drug Substitution" by people in Profiles.

Deaner JD, Srivastava SK, Hajj-Ali RA, Lowder CY, Venkat AG, Baynes K, Sharma S. Recurrence Rates of Inflammation after Switching from the Originator Infliximab to Biosimilar Infliximab-abda for Noninfectious Uveitis. Am J Ophthalmol. 2021 05; 225:172-177.

View in: PubMed
Dal?n J, Luttropp K, Svedbom A, Black CM, Kachroo S. Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-a Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study. Adv Ther. 2020 09; 37(9):3746-3760.

View in: PubMed
Sharma A, Hafeez Faridi M, Kumar N, Parachuri N, Sharma R, Kuppermann BD, Bandello F, Loewenstein A, Regillo CD. Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data. Eye (Lond). 2020 06; 34(6):1008-1009.

View in: PubMed
Lo KBU, Azmaiparashvili Z. Desquamating pustular rash. Cleve Clin J Med. 2019 12; 86(12):780-781.

View in: PubMed
Crawford ED, Tombal B, Keane T, Boccardo F, Miller K, Shore N, Moul JW, Damber JE, Collette L, Persson BE. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist. Scand J Urol. 2018 Oct - Dec; 52(5-6):349-357.

View in: PubMed
Gajanana D, Weintraub WS, Kolm P, Rogers T, Iantorno M, Buchanan KD, Ben-Dor I, Pichard AD, Satler LF, Thourani VH, Torguson R, Okubagzi PG, Waksman R. The impact of in-hospital P2Y12 inhibitor switch in patients with acute coronary syndrome. Cardiovasc Revasc Med. 2018 12; 19(8):912-916.

View in: PubMed
O'Brien EC, Holmes DN, Thomas L, Fonarow GC, Kowey PR, Ansell JE, Mahaffey KW, Gersh BJ, Peterson ED, Piccini JP, Hylek EM. Therapeutic Strategies Following Major, Clinically Relevant Nonmajor,?and Nuisance Bleeding in Atrial Fibrillation: Findings From?ORBIT-AF. J Am Heart Assoc. 2018 06 09; 7(12).

View in: PubMed
Dal?n J, Svedbom A, Black CM, Kachroo S. Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors. Rheumatol Int. 2017 Dec; 37(12):2049-2058.

View in: PubMed
Essebag V, Proietti R, Birnie DH, Wang J, Douketis J, Coutu B, Parkash R, Lip GYH, Hohnloser SH, Moriarty A, Oldgren J, Connolly SJ, Ezekowitz M, Healey JS. Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial. Europace. 2017 Oct 01; 19(10):1630-1636.

View in: PubMed
Teo KC, Lau GKK, Mak RHY, Leung HY, Chang RSK, Tse MY, Lee R, Leung GKK, Ho SL, Cheung RTF, Siu DCW, Chan KH. Antiplatelet Resumption after Antiplatelet-Related Intracerebral Hemorrhage: A?Retrospective Hospital-Based Study. World Neurosurg. 2017 Oct; 106:85-91.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement